sfondo pallini

& Media

Below you can fin all our press releases and company info

Quince Therapeutics to Acquire EryDel SpA

Quince is pleased to announce that it has entered into an agreement to acquire EryDel SpA, a privately-held, late-stage biotech company with an innovative autologous intracellular drug encapsulation (AIDE) technology and a Phase 3 lead asset, EryDex.

EryDex targets a rare fatal pediatric neurological disease, Ataxia-Telangiectasia, which currently has no approved treatments and represents an estimated $1+ billion peak sales opportunity.

Learn more about the EryDel acquisition:

News Release Presentation